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The adoptive transfer of antigen-speciﬁc cytotoxic T lymphocytes (CTL) shows promise in the treatment of cancer and infectious
diseases. We utilize adeno-associated virus-(AAV-) based antigen gene-loaded dendritic cells (DCs) to stimulate such antigen-
speciﬁc CTL. Yet further improvements in CTL stimulation and killing may result by gene delivery of various Th1-response
interferons/cytokines,suchasinterferonγ (IFN-γ),asthedeliveredgenecancontinuouslyproducethatinterferon.Howeverwhich
immune cell type should optimally express IFN-γ is unclear as the phenotypes of both DC and T cells are enhanced by it. Here,
we used AAV to compare and contrast IFN-γ gene delivery into DC or T cells, and versus the addition of exogenous IFN-γ,f o r
stimulatingcarcinoembryonicantigen-(CEA-)speciﬁcCTL.ItwasfoundthatAAV/IFN-γ deliveryintoTcells(autocrine)resulted
in T cell populations with the highest CD8(+)/CD4(+) ratio, highest IFN-γ(+)/IL-4(+) ratio, highest CD69(+),CD8(+) levels, and
lowest CD4(+)/CD25(+) levels, all consistent with the strongest Th1 response. Most importantly, AAV/IFN-γ transduction of T
cells resulted in antigen-speciﬁc T cell populations with the highest killing capabilities, 49% above other treatments. These data
strongly suggest that AAV/IFN-γ autocrine gene delivery into T cells is worthy of further study towards maximizing the generation
of antigen-speciﬁc anticancer CTL killers.
1.Introduction
Adoptive immunotherapy, particularly adoptive transfer of
antigen-speciﬁc cytotoxic T lymphocytes, has shown some
success in clinical trials for treating both cancer and viral
infections [1–5]. However, due to resident tolerance within
the tumor environment the most robust CTL must be
stimulated for highest eﬃcacy. Delivery of antigen genes
into dendritic cells (DCs) or precursor monocytes (Mo)
allows for the stimulation of robust antigen-speciﬁc CTL [6].
However, there are a variety of improvements that might
be made to further enhance CTL stimulation. One obvious
course is the delivery of Th1-response interferons/cytokine
genes into immune cells for their continuous expression.
Interferon gamma (IFN-γ) is an important Th1 response
interferon/cytokineinvolvedinCTLgenerationandfunction
and might be used to enhance CTL stimulation. IFN-γ likely
has multiple mechanisms of action [7–10]. It is believed to
inhibit expression of the IL-4 receptor. This is important
as IL-4 correlates with low and ineﬀective CTL activity.
In addition, IFN-γ may have other non-T cell-associated
attributes as it is believed to stimulate expression of HLA
Class I and II molecules. However, overall IFN-γ is strongly
linked to the induction of Th1 response, the generation of2 Journal of Biomedicine and Biotechnology
CTL. Of all the Th1 response interferons/cytokines IFN-γ
correlates most strongly with the Th1 response [9–11]a s ,
in fact, many laboratories study T cell expression of IFN-
γ as a substitute for carrying out CTL killing/chromium
release assays [12, 13]. Moreover, IFN-γ plus IL-12 appears
to act cooperatively in the generation of a very strong Th1
response [14, 15]. IFN-γ may also partially overcome low
activation and expansion rates of low-avidity CTL [16, 17].
As with most of the Th1-response-associated chemokines,
IFN-γ is associated with regulation of perforin/Granzyme B
[18]. Thus, gene delivery of IFN-γ will likely be very useful in
generating a robust Th1 CTL response.
While IFN-γ gene delivery would seem to be beneﬁ-
cial for generating robust CTL, it is unclear which cells
should speciﬁcally express this cytokine for maximum CTL
stimulation. While activated T cells naturally express IFN-
γ, it has been shown that IFN-γ is able to signiﬁcantly
aﬀect DC maturity and function as well as DC precursor
Mo and macrophage (MΦ)p h e n o t y p e s[ 19–21]. Thus it is
unclear which immune cell type should express this cytokine
during the initial stimulation of the CD8+ CTL. Two general
approaches are available, transducing the DC (paracrine
delivery) which stimulate the responder T cells, or the T cell
themselves (autocrine delivery). Here we demonstrate that
IFN-γ autocrine gene delivery resulted in signiﬁcantly higher
CEA-speciﬁc CTL killing compared with paracrine delivery
or exogenous IFN-γ.
2.MaterialsandMethods
2.1. Cells. The SW480 colorectal adenocarcinoma cell line
was obtained from The American Tissue Culture Collec-
tion (ATCC). A carcinoembryonic antigen- (CEA-) positive
lymphoblastoid cell line (CEA+ LCL) was generated by
transfecting an HLA-A2 positive LCL cell line with a CEA
plus Neomycin resistance gene (Neo) expression plasmid
and selection with 1mg/mL G418 for two weeks. Periph-
eral blood mononuclear cells (PBMCs) from ﬁve HLA-A2
positive healthy donors were separated by routine Ficoll
gradient method. All blood donors gave informed consent
in writing, and the study protocol conformed to the ethical
guidelines of the 1975 Declaration of Helsinki as reﬂected in
a priori approval by our Human Research Internal Review
Board.TheHLAhaplotypeofalldonorswascompatiblewith
SW480 cells (HLA A2) and other cells used as controls.
2.2. Construction of Recombinant AAV Vectors. Human CEA
and IFN-γ cDNAs were ampliﬁed by reverse-transcription
polymerase chain reaction (RT-PCR). Trizol reagent (Invit-
rogen) was employed to isolate total RNA from SW480
cells and PHA-stimulated primary human T lymphocytes,
respectively. Subsequently, the total mRNA was separate
from the total RNA using Oligotex mRNA isolation kit
(Qiagen). After the ﬁrst-strand cDNA was generated, PCR
ampliﬁcation for each of the cDNA was carried out using
the following primer pair: CEA: 5 -ACCATGGAGTCTCCC-
TCG-3  and 5 -CTATATCAGAGCAACCCC-3  that amplify
the sequence from nucleotides 112 to 2223 [22]; IFN-γ:5  -
TTCTCTCGGAAACGATG-3  and 5 -GGCAGGACAACC-
ATTAC-3  that amplify the sequence from nt 94 to 622 [23].
All cDNAs were sequenced and determined to be identical
to the published sequence. CEA and IFN-γ cDNA were
insertedinthedownstreamofp5promoterofanAAVvector,
respectively, as described previously [24].
2.3. Transduction of DC by Recombinant AAV. The exper-
imental scheme is shown in Figure 1. The rAAVs were
generated, puriﬁed, and tittered as described previously [24,
25].Titerisgivenasencapsidatedgenomes(eg)permL.After
freshly isolated PBMCs (5×106)w e r ec u l t u r e df o rt w oh o u r s
in AIM-V medium, the nonadherent cells were removed.
The remaining adherent Mos were infected immediately
with 1 × 109 encapsidated genomes (eg)/mL of AAV/CEA
virus or AAV/CEA plus AAV/IFN-γ virus. After four hours
the medium/virus solution was removed and the cells were
ﬁnally fed with the medium containing recombinant human
GM-CSF (Immunex, 800IU/mL). At day 2, to induce the
maturation of Mo into DC, recombinant human IL-4 and
TNF-α (R & D SYSTEMS.) were added to the medium at
1000IU/mL and 20ng/mL, respectively. The medium and
cytokines were replaced every two days. Finally, at day 6 the
DCs were mixed with CD3+ T cells.
2.4. Transduction of CD3+ T Cells by Recombinant rAAV. T
cells were transduced as described previously [25]. Brieﬂy,
Pan T Cell Isolation Kit II (Miltenyi Biotec) was employed
to isolate CD3+ T cells from the nonadherent cells from the
PBMC according to the kit instruction. At day 5 the CD3+ T
cells (1×106)wereinfectedwith1×109 eg/mLofAAV/IFN-γ
virus and cultured with 20ng/mL of IL-2.
2.5. Analysis of rAAV Chromosomal Integration. The total
DNAs were isolated from the rAAV-infected or uninfected
DC or T cells using DNAzol reagent (Invitrogen) accord-
ing to supplier’s protocol. Chromosomal integration of
the AAV/CEA genome was studied by vector-chromosome
junction PCR ampliﬁcation and southern blot analysis, as
previously described [24].
2.6. RT-PCR Expression Analysis of Transduced DC or T
Cells for CEA and IFN-γ Expression. At day 4 of Mo/DC
culture and DC-T cell culture, isolation and ampliﬁcation
of the mRNA was done as described above, respectively.
Subsequently, the CEA and IFN-γ cDNAs were ampliﬁed
as described above. TFIIB was ampliﬁed as a housekeeping
control at the same time. PCR ampliﬁcation for the TFIIB
cDNA was performed using the primer pair: 5 -TGTCTG-
TTGTGTCTTGTTGC-3  and 5 -TAGGCTATGTACAAC-
AGGC-3  thatamplifythesequencefromnt319to1310[26].
2.7. Analysis of Transduction and Expression of CEA Antigen
and Cytokines by Intracellular Staining. At day 6 of Mo/DC
culture and day 4 of rAAV infection of CD3+ T cells,
intracellular staining assay was employed, similar to Pala
et al. [27]. Brieﬂy, cells were incubated with the FITC- orJournal of Biomedicine and Biotechnology 3
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Figure 1: Structure of the cell treatment protocol. Shown is the temporal treatment of the Mo/DC and T cells and is self-descriptive.
However, note that AAV/IFN-γ is used to infect Mo/DC at day zero, or naive T cells just prior to coincubation with AAV/antigen-loaded DC
on day 5.
PE-labeled monoclonal antibodies recognizing the following
antigens, respectively: CEA, IFN-γ, and IL-2 (BD Pharmin-
gen). Control irrelevant isotype-matched FITC- or PE-
conjugated monoclonal antibodies were also obtained from
BD Pharmingen. A FACSCalibur ﬂow cytometer (Becton-
Dickinson) was used for data acquisitions. At least ten
t h o u s a n de v e n t sw e r ec o u n t e df o re a c hs a m p l e .
2.8.StimulationofCytotoxicTLymphocytes(CTLs)byTreated
DC. At day 5-6 of DC culture the mature DCs were
harvested and mixed with CD3+ T lymphocytes (ratios from
20:1, T:DC) in AIM-V medium, respectively. Some T cells
were untransduced while others were previously infected
with AAV/IFN-γ. Mixtures were cultured in AIM-V contain-
ing IL-2 (20IU/mL) and IL-7 (20ng/mL). The medium and
cytokines were replaced every two days. Exogenous IFN-γ
was used at 100U/mL. At 7-8 days postaddition to DC the
cells were harvested and analyzed further.
2.9. FACS Analysis of DC and T Cells. After 6 days the
nonadherentDCswereharvested(>95%viableasassessedby
Trypanblueexclusion)andthecellscountedanddistributed.
For the analysis of DC a panel of FITC- or PE-labeled
monoclonal antibodies recognizing the following antigens
was used: CD14, CD40 (Chemicon International), HLA-
DR, CD80, CD8, CD86, and isotype-matched antibodies
(BD Pharmingen). Stained cells were assayed by ﬂuorescence
activated cell sorting (FACS) for these CD markers according
to the routine method [25]. For the analysis of activated T
cells, at day 8 of the mixed cell culture the stimulated T
cell populations were analyzed for their surface markers with
immunoﬂuorescence staining by ﬂow cytometry. A panel
of FITC- or PE-labeled monoclonal antibodies recognizing
the following antigens was used: CD4, CD8, CD25, and
CD69 (BD Pharmingen). At day 8 postpriming T cells
were harvested for analysis. Intracellular staining assay was
performed to analyze the expression of IFN-γ in the T cells
accordingtothemethoddescribedabove.FITC-labeledanti-
IFN-γ monoclonal antibody (BD Pharmingen) was used.
2.10. Analysis of T Cell Proliferation Stimulated by rAAV-
Infected DC. After the CD3+ T cells were mixed with the DC
on day 6, each group of mixed cells was inoculated into wells
ofa96-wellcellcultureplate.Therewere5×105 cells(200μl)
ineachwell.Afterthemixedcellswereculturedfor8hoursin
37
◦C, 5% CO2, 3H-TDR incorporation test was carried out
according to the routine method [25].
2.11. Analysis of CTL Killing Activity. CTLs were generated
from 3 donors. At day 14 (day 8 of T cell: DC coincubation),
chromium-51 (51Cr) release assay was used to analyze the
killing activity of CTL elicited by AAV/CEA-transduced and
control DC against the target cells as previously described
[25]. Brieﬂy, the CTL cells and 51Cr-labeled target cells4 Journal of Biomedicine and Biotechnology
Table 1: Surface expression of CD molecules on DC, as percentage.
DC treatment CD14 CD40 CD80 CD83 CD86 HLA-DR
Ctrl (mock) 20.7 21.6 29.8 22.2 63.7 90.1
AAV/CEA 14.5 41.3 62.1 42.6 88.5 94.5
AAV/CEA + exo IFN-γ 16.3 40.0 60.4 39.9 86.2 90.3
AAV/CEA + AAV/IFN-γ 12.5 42.4 65.1 43.1 89.5 96.2
M
a
r
k
e
r
C
t
r
l
A
A
V
/
I
F
N
-
γ
7kb>
2kb>
(a)
M
a
r
k
e
r
C
t
r
l
A
A
V
/
I
F
N
-
γ
(b)
Figure 2: Chromosomal integration of AAV/IFN-γ vector DNA
intoDCandTcells.CellswereinfectedasdescribedintheMaterials
and Methods section and then analyzed for proviral integration
by, ﬁrst, PCR ampliﬁcation of the vector-chromosomal junctions,
followed by agarose gel electrophoresis of the PCR products,
Southern blotting and probing with
32P labeled vector DNA. Each
bandrepresentsaseparateAAVintegrantwithinthecellpopulation.
(a) shows the results from DC. (b) shows the results from T cells.
were mixed (20:1) and incubated for 6 hours at 37
◦Cw i t h
5% CO2. To determine MHC/HLA Class I restriction of
CTL killing anti-MHC Class I monoclonal antibodies were
used to block cytotoxicity. The 51Cr-labeled targets were
preincubated with mouse antihuman MHC class I antibody
(Serotec) for 1 hour before the 51Cr release assay was
p e r f o r m e d .T h em o u s ea n t i h u m a nM H Cc l a s sI Ia n t i b o d y
(Serotec) was also used as a control.
3. Results
3.1. Cloning of CEA, IFNγ,a n dD e l i v e r yi n t oD Ca n dTC e l l s .
The CEA gene, a common adenocarcinoma tumor marker,
was cloned from colorectal adenocarcinoma cell line SW480
and ligated down-stream of the AAV p5 promoter within
a fully gutted AAV2-based vector (dl3-97). IFN-γ was also
successfully cloned into AAV in a similar manner. rAAVs
were generated as described previously [24, 25]a n du s e d
to transduce DC and T cells at eﬃciencies above 85%. Our
approach for transducing DC has been to infect freshly
adherent peripheral blood monocytes with rAAV, to treat
these cells with GM-CSF alone for one day, and then add
IL-4 to induce their diﬀerentiation into DC [24, 25, 28].
This technique has proven to be very eﬀective in generating
speciﬁc antigen-presenting DC and cytokine-expressing DC
[24, 25, 28].
3.2. rAAV Proviral Chromosomal Integration and Expression
of CEA and IFNγ. One issue in the ﬁeld of AAV-based
gene therapy is the form of latency of the AAV proviral
DNA within the transduced primary cells. In vitro tissue
culture transduced cell lines often display a chromosomally
integratedprovirus,whileinvivotransducedcellsoftenshow
the latent rAAV DNA as an episomal element. To address
this issue chromosomal DNA from the transduced T cells
and DC were analyzed for integrated AAV/IFN-γ provirus by
PCRampliﬁcationofvector-chromosomejunctionsbyusing
one primer directed towards the vector and another directed
towards the Alu I repetitive chromosomal element. Products
were then agarose gel electrophoresed, Southern blotted, and
32P-DNA probed for vector sequences. As shown in Figures
2(a) and 2(b) this technique clearly demonstrates some level
of chromosomal latency in both DC and CD3+ T cells. We
have previously shown AAV/CEA chromosomal integration
in DC [25].
It is important that rAAV proviruses express their
transgenes. Figures 3(a) and 3(b) show that the resulting
rAAV/IFN-γ provirus does express by RT-PCR analysis, in
both DC and T cells. To observe both the transduction
eﬃciency and protein expression of IFN-γ we carried out
an intracellular staining analysis of transduced and untrans-
duced DC and T cells. The transduction eﬃciency of DC by
AAV/IFN-γ,asshowninFigure 4(a)(DC)andFigure 4(b)(T
cells), approached 90%. This agrees with our earlier studies
with other transgenes, but it must be noted that T cells
which were not transduced with AAV/IFN-γ displayed a high
background expression of 48%. In any case, transduction
eﬃciency using AAV 2 was high for both the DC and T cells.
3.3. Characterization of Transduced DC. The structure of the
experimentalschemeisshowninFigure 1.WeinfectDCwith
either the AAV/cytokine vector at day 0 or the T cells on day
5 just before their addition to the CEA antigen loaded DC.
DCs(Mo)werealwaysloadedbyinfectionwithAAV/CEAon
day 0. We examined the DC on day 6, as shown in Table 1,
for surface expression of CD14, CD40, CD80, CD83, and
CD86 by FACS and found that CD80, CD86, and CD83 were
upregulated by rAAV infection as shown previously [29].
The addition of exogenous IFN-γ further upregulated theseJournal of Biomedicine and Biotechnology 5
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Figure 3: Analysis of IFN-γ expression in transduced DC and T cells by RT-PCR. Cells were infected, mRNA isolated and analyzed by RT-
PCR as described in Section 2. (a) shows the results from DC. (b) shows the results from T cells. Note that both AAV/IFN-γ transduced DC
and T cells demonstrate IFN-γ expression. Also note that untransduced T cells expressed some IFN-γ,b u tt h a tA A V / I F N - γ transduced T
cells demonstrate higher IFN-γ expression. This is conﬁrmed in Figure 4.
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Figure 4: Transduction eﬃciency of AAV delivery into DC and T cells by intracellular staining. Cells were infected as described in Section 2
and analyzed by intracellular staining for IFN-γ. (a) shows the results from DC infection. (b) shows the results from T cell infection. Note
that both AAV/IFN-γ transduced DC and T cells demonstrate high levels of IFN-γ expression, but that T cells exhibit a signiﬁucant basal
level of expression.6 Journal of Biomedicine and Biotechnology
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Figure 5: IL-12 and IL-10 expression in DC Analysis of IL-12 and IL-10 expression in DC under treatment with exogenous IFN-γ treatment
versus AAV/IFN-γ transduction. Note that the IL-12/IL-10 ratio was slightly enhanced by AAV/IFN-γ transduction.
markers, but the use of AAV/IFN-γ had a more profound
eﬀect.
We further observed the resulting expression level of
IL-12 and IL-10 in DC by these various treatments, as
shown in Figure 5. DCs were treated with exogenous IFN-
γ or AAV/IFN-γ. A high IL-12/IL-10 ratio reﬂects the
likelihood that these DCs would stimulate a more robust
Th1 CTL response; however both treatments gave a similar
ratio. Secretion of IFN-γ from DC (and T cells) was
also measured by ELISA. IFN-γ secretion from AAV/IFN-
γ transduced DC, with or without AAV/CEA transduction,
shown in Figure 6, was similar. Expression rose from 68
to 80 hours postinfection and then remained stable out
to 92 hours. However, it is noteworthy that AAV/IFN-γ-
infectedTcellssecretemoreIFN-γ thanAAV/IFN-γ-infected
DC.
3.4. Characterization of Transduced and Stimulated T Cells.
A robust MHC/HLA Class I-restricted Th1 CTL response is
most consistent with a high CD8:CD4 ratio. The resulting
cell population stimulated by the various DC treatments
was analyzed by FACS and the results listed in Table 2
upper panel. The CD8/CD4 ratio in T cell populations
was higher when these cells were stimulated by AAV-
transduced DC than with mock-treated DC (Table 2).
However T cells derived from AAV/IFN-γ-treated DC had
a slightly higher CD8/CD4 ratio, consistent these cells
having slightly higher CD80, CD83, and CD86 expression
(Table 1), and slightly lower IL-10 expression (Figure 5).
However, the direct treatment of T cells by AAV/IFN-
γ, stimulated by AAV/CEA-loaded DC, resulted in T cell
populations with the highest CD8/CD4 ratio (7.9) (Table 2
lower panel).
A robust Th1 CTL response is also consistent with
ah i g hI F N - γ/IL-4 expression ratio. Again, the resulting
T cells generated from any AAV-transduced DC had a
higher IFN-γ/IL-4 expression ratio than by mock treated
DC (Table 2 upper panel). However, the direct treatment of
T cells with AAV/IFN-γ delivery, stimulated by AAV/CEA
loaded DC, resulted in T cell populations with the highest
IFN-γ/IL-4 ratio (18.3) (Table 2 lower panel). Moreover,
a robust Th1 CTL response is also consistent with a
high proportion of CD69+/CD8+ T cells. Yet again, the
direct treatment of T cells by AAV/IFN-γ, stimulated by
AAV/CEA loaded DC, resulted in T cell populations with
the highest percent of CD69+/CD8+ T cells (91.3%) (Table 2
lower panel). Finally, a robust Th1 CTL would also be
consistent with low CD25+/CD4+ Treg cell numbers. Again,
the direct treatment of T cells by AAV/IFNγ, stimulated
by AAV/CEA loaded DC, resulted in T cell populations
with the lowest percent of CD25+/CD4+ Treg cells (17.1%)
(Table 2 lower panel). Taken together these data suggest
that AAV/IFNγ autocrine-delivery into T cells oﬀers the
most powerful Th1-T cell population as measured by
the CD8/CD4 ratio, IFN-γ/IL-4 ratio, highest percentage
CD69+, CD8+ cells, and lowest percent CD25+, CD4+
cells.
The generation of responder CTL involves both the
proliferation of CD4+ helper T cells as well as proliferation
of the CD8+ T cells themselves. To test the level of T cell
proliferation we carried out the standard protocol for the
generation of antigen-speciﬁc CTL. However, in addition to
loading the DC with the antigen (AAV/CEA) we also added
the delivery of AAV/IFN-γ into DC or T cells. Proliferation
of CD3+ T cells was measured by the incorporation of
3H-TdR, and the results are shown in Figure 7.I ta p p e a r s
that the use of IFN-γ in any form oﬀered no advantage toJournal of Biomedicine and Biotechnology 7
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Figure 6: Secretion of IFN-γ from AAV-transduced cells over time. Cells were treated as indicated and secretion of IFN-γ was measured in
the conditioned medium at the indicated time by ELISA. The conditions include AAV/IFN-γ delivery into DC (with concurrent AAV/CEA
delivery), (a); AAV/IFN-γ delivery into T cells, (b); AAV/IFN-γ only delivery into DC, (c); cells with no treatment, (d).
that of the stimulation of proliferation by AAV/CEA-loaded
DC. Overall T cell proliferation is relatively equal among
all treatments (Figure 7), while the CD8/CD4 ratio increases
(Table 2) when T cells are AAV/IFN-γ-infected. This suggests
that CD8+ T cells are preferentially stimulated to proliferate.
3.5. Autocrine IFN-γ Gene Delivery Enhances CTL Killing.
Having characterized the AAV/IFN-γ transduced DC and T
cells we then assayed the resulting CTL for their ability to kill
a genetically altered CEA-positive lymphoblastoid cell line
(LCL) which was HLA A2-matched with blood donors. To
do this we carried out the experiment depicted in Figure 1
and tested for SW480 cell target killing using the standard
51Crreleaseassay,andtheresultsareshowninFigure 8(a).As
can be seen the highest level of CEA-directed killing results
from AAV/IFN-γ autocrine delivery into T cells, a 49%8 Journal of Biomedicine and Biotechnology
Table 2: Characterization T cell subsets and cytokine expression as percentages, from AAV-infected DC (top panel) and rAAV-infected T
cells (bottom panel).
DC treatment CD8+/CD4 IFN-γ/IL4 CD69+, CD8+ CD25+, CD4+
Ctrl (mock) 21.6/51.3 21.85/10.75 27.4 55.6
AAV/CEA 50.3/22.1 26.53/2.73 61.5 16.2
AAV/CEA + exogen IFN-γ 52.1/23.6 18.84/2.46 60.8 15.6
AAV/CEA + AAV/ IFN-γ 56.5/22.5 27.71/2.90 64.7 14.3
T cell treatment CD8+/CD4+ IFN-γ/IL4 CD69+, CD8+ CD25+, CD4+
AAV/IFN-γ 84.6/10.7 43.4/2.37 91.3 17.1
exogen IFN-γ ND 24.28/1.96 ND ND
Untreated T cells 14.1/69.8 26.53/2.73 20.5 63.5
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Figure 7: Proliferation of T cells. Tritium incorporation by T cells
is shown under various treatments.
increase over AAV/CEA-only control. Killing was blocked by
polymorphic anticlass I antibody, but not by anticlass II. The
highkillingthatresultsfromAAV/IFN-γ autocrinetreatment
is fully consistent with the highest CD8/CD4 ratio, highest
IFN-γ/IL-4 ratio, highest percentage CD69+, CD8+ cells,
and lowest percent CD25+, CD4+ cells. The higher killing
may be attributed to the higher CD8+ T cell number due
to higher CD8/CD4 ratio of T cells in AAV/IFN-γ-treated
bulk T cell cultures versus the lower ratio generated from
AAV/IFN-γ-treated DC, 84.6%/10.7% versus 56.5%/22.5%,
respectively (Table 2). We also utilized CEA+ LCL cells as a
target and, again, AAV/IFN-γ autocrine delivery into T cells
resulted in CTL with the highest killing of CEA+ LCL, shown
in Figure 8(b).
4. Discussion
While IFN-γ has multiple actions which promote Th1
response [7–10], it was unclear which immune cell type
should best express this cytokine. This study demonstrates
that only a speciﬁc approach of IFN-γ gene delivery,
autocrine delivery, results in a CD3+ T cell population
with higher killing ability. This was not fully anticipated
as IFN-γ aﬀects the phenotype of both DC and T cells.
For DC IFN stimulates signiﬁcantly higher MHC class II,
CD86, and slightly higher CD80 levels [30–32]. IFN-γ also
stimulates higher IL-12 expression and DC maturation [30–
32]. Comparing DC from IFN knockout mice and normal
mice, IFN-γ expression by DC also appears needed for
the eﬀective CD8+ T cell stimulation [33]. Normally IFN-
γ expression in DC is dependent upon T-bet [34], but in
this study we have circumvented this need by expressing it
from the CMV promoter within the AAV backbone (AA).
Moreover, NK and NKT cells are believed to be the major
sources of IFN-γ for induction of macrophage maturation
[35]. This pathway has also been circumvented by AAV/IFN-
γ delivery. Paracrine IFN-γ expression by DC is believed
to stimulate T cells to autocrine express their own IFN-
γ.H o w e v e r ,I F N - γ also has pronounced eﬀects on T cells
as well. While IFN-γ inhibits the formation of Th2 cells
[36], its expression directly correlates with the formation
of Th1 response and CTL killing, as mentioned earlier, so
much so that IFN-γ secretion is used as a substitute for
antigen speciﬁc killing assays [12, 13]. Yet IFN-γ appears
needed for the activity of unusual CD8(+)LAP(+)foxp3(+)
Treg cells. Thus, there is some evidence that IFN-γ may
ultimately turn oﬀ the Th1 response that produces it
[37].
Our purpose for these studies was to further analyze
the mechanism of action of IFN-γ and to optimize ex vivo
generated anticancer CTL for adoptive therapies in cancer.
While the adoptive transfer of ex vivo manipulated dendritic
cells (DCs) appears mostly ineﬀective in anticancer therapies
[38], the adoptive transfer of ex vivo generated anti-cancer
CD8+ MHC Class I-restricted cytotoxic T lymphocytes
(CTLs) seem to be a more promising treatment therapy
[39, 40]. While this study demonstrates that IFN-γ is best
delivered and expressed via the autocrine route in the
generation of antigen-speciﬁc CD8(+) CTL, it should be
pointed out that the basal levels of natural IFN-γ expression
also remain present and we are simply augmenting the level
of IFN-γ. Thus, our interpretation of this data is that most
likely the maximum eﬀective ceiling of IFN-γ expression
and eﬀect in DC had been reached, while the eﬀective
ceiling of IFN-γ expression and eﬀect in T cells had not
been.Journal of Biomedicine and Biotechnology 9
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Figure 8: Enhanced CTL killing by IFN-γ autocrine delivery. (a) shows CTL killing after the indicated treatment, of CEA-positive targets,
SW480 cells, by standard
51Cr release assay. All assays were done at a eﬀector: target ratio of 20:1. Note that AAV/IFN-γ autocrine delivery
resulted in CTL with the highest killing ability. (b) shows a similar CTL killing assay using CEA+ LCL cells as the target. Note that, again,
AAV/IFN-γ autocrine delivery resulted in CTL with the highest killing ability.
Another advantage of IFN-γ overexpression in CTL
would be its known ability to upregulate MHC class I
molecules, allowing for enhanced recognition of antigen
expressing tumor cells [41]. Yet the practicality of the
autocrine approach for certain Th1 response cytokines
is questionable as the endogenous expression of certain
cytokines in Th1 T cells may be problematic. The transgenic
expression of IL-15 is linked with malignancy [42]. The
most similar study involving IFN-γ was by Young et al., who
generated transgenic mice which overexpressed IFN-γ in the
t h y m u sa n ds p l e e n[ 43]. While bone-related granulomatous
lesions and degeneration of cartilage was observed, there
were no serious hyperproliferative cellular elements seen in
thebonemarrow,spleen,orlymphnodes.Thus,theadoptive
transferofIFN-γ-over expressing T cells in clinical trials may
be further considered. In fact we observed no advantageous
proliferation by the T cells (Figure 7). Moreover, if further
work suggests that there are serious side eﬀects of IFN-γ
overexpression in T cells, then the inclusion of a suicide
gene within the vector, such as herpes thymidine kinase
gene, would allow for the elimination of these cells when
needed.
This head-to-head comparison of IFN-γ overexpression
in DC versus T cells was done with the purpose of enhancing
Th1 CD8(+) CTL response. However, these data also give us
information as to the primary mechanism of action of IFN-
γ o nT h 1i m m u n er e s p o n s em a yb et h r o u g he n d o g e n o u sT
cell expression. Yet further analysis is needed to determine
whether it is the CD4(+) or CD8(+) T cell which is the
primary vehicle through which IFN-γ acts. Cell ratio studies
(Table 2) suggest that it is the CD8(+) T cell. Ultimately
DNA microarray analysis of the T cell’s transcriptome and
proteomics analysis are warranted to fully understand how
high IFN-γ expression aﬀects the cell’s phenotype.
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